Share Your Research, Maximize Your Social Impacts
Melasma like hyperpigmentation on face: A rare side effect of imatinib
Journal: Annals of Geriatric Education and Medical Sciences (Vol.5, No. 2)Publication Date: 2018-09-28
Authors : Anusha Gupta Sunil Kumar Saurav Chaturvedi Apoorva Nirmal;
Page : 79-80
Keywords : Drug-induced pigmentation; Imatinib-mesylate; Melasma; Chronic myeloid leukemia.;
Source : Download
Find it from : Google Scholar
Abstract
Imatinib mesylate is a cytotoxic agent that is used in chronic myeloid leukaemia. Common reported side effect is hypopigmentation; here we report a 48 year old female who developed hyperpigmentation as melasma on her face while taking imatinib mesylate in a dose of 400 mg daily for chronic myeloid leukaemia.
Other Latest Articles
- New Information on the Psocoptera fauna of the Bulgarian Black Sea Coast
- RELATIONSHIP BETWEEN PRINCIPALS LEADERSHIP PRACTICES, TEACHERS PROFESSIONAL COMMUNITIES & ORGANIZATIONAL COMMITMENT
- SD-OCT in evaluation of microstructural changes in macula following blunt ocular trauma
- New Palaeobotanical Data From The Satovcha Graben (Southwest Bulgaria)
- Paroxysmal dyskinesia presenting feature of hyperthyroidism in an elderly: A case report
Last modified: 2019-08-30 19:04:58